Polycystic ovary syndrome and obesity: a modern paradigm

Polycystic ovary syndrome is a heterogeneous endocrine disease that affects women of childbearing age. The pathogenesis polycystic has not been fully studied to date, its paradigm considers the genetic determinism manifestation hormonal and metabolic disorders, which are considered be criteria for verification (hyperandrogenism, oligo/anovulation and/or ovarian transformation during ultrasound examination (ultrasound). This review discusses main ways interaction between hyperandrogenism, insulin resistance obesity their role in syndrome, as well possible methods treatment this category patients. analyzes hyperandrogenism implementation scenario finds out reasons why with often demonstrate presence «metabolic trio» - hyperinsulinemia, type 2 diabetes mellitus. It noted included diagnosis but epidemiological data confirm existence relationship these diseases. Obesity, especially visceral, found enhances worsens reproductive outcomes increases compensatory which, turn, stimulates adipogenesis suppresses lipolysis. Obesity sensitivity tech cells luteinizing hormone stimulation functional ovaries, increasing production androgens by ovaries. Excess body weight associated large number inflammatory adipokines, contribute growth adipogenesis. exacerbate symptoms forming vicious circle contributes development syndrome. These allow us conclude bariatric surgery can become an alternative drugs (metformin, thiazolidinedione analogs glucagon-like peptide-1), shown positive results patients obesity.